Kaken Pharmaceutical To Go Ex-Dividend On March 28th, 2025 With 75 JPY Dividend Per Share

March 27th (Japan Standard Time) - $Kaken Pharmaceutical(4521.JP)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 75 JPY dividend per share. The ex-

Futu NewsMar 27 09:00

Research pharmaceuticals continue to rise, regarded as a material for the conclusion of a licensing agreement with the American Aluminum company.

The research pharmaceutical company <4521.T> continues to rise, temporarily reaching a 21 yen increase to 4,600 yen. After the market closes on the 25th, it was announced that a licensing agreement has been signed with the American company Alumis (Alumis Inc., California) regarding the development, manufacturing, and commercialization in Japan of "ESK-001" (development code), which is under development for conditions such as psoriasis. The company states that this licensing agreement will enable the advancement of "ESK-001" in the dermatology field in Japan.

Kabushiki ShimbunMar 26 12:37

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

GlobeNewswireMar 25 14:30

The research pharmaceutical company has signed a comprehensive collaboration agreement with Fujieda City, Shizuoka Prefecture, to promote health and prevention and to advance the Region's industry ETC.

On the 19th, the research pharmaceutical company <4521.T> announced that it has signed a comprehensive partnership agreement with Fujieda City in Shizuoka Prefecture for the promotion of health and prevention and the revitalization of local industries. With this agreement, cooperation will take place in the following areas: (1) matters related to the promotion of health and prevention, (2) matters related to the promotion and revitalization of local industries, (3) matters related to environmental conservation and coexistence, (4) matters related to Mainland Education and human resource development, (5) QITABANKUAI, and other necessary matters to realize the 'Health City Fujieda'. As of 1 PM, the stock price is

Kabushiki ShimbunMar 19 12:02

List of conversion stocks (part 3) [Parabolic Cigna Corp conversion stocks list]

○ List of stocks that have switched to Sell market Code Stock Name Closing Price SAR Main Board <2374> Sentcare HD 741 754 <2502> Asahi 1925 1937 <2540> Yomeishu 2605 2680 <2811> Kagome 2998 3076 <3183> Win P 1463 1595 <3199> Watanabe HD 1698 1738 <3387> Crelis HD 1278 1344 <3480> J-E.

Fisco JapanMar 18 06:44

JACOBSON PHARMA: ULFERTS Pharmaceuticals and Li Zhongsheng Hall have established a licensing agreement for 2025.

JACOBSON PHARMA (02633) and JBM HEALTHCARE (02161) jointly announced that on February 28, 2025, ULFERTS and Li Zhong Sheng Tang entered into the 2025 licensing agreement, under which ULFERTS agrees to allow Li Zhong Sheng Tang to use part of the factory according to the terms and conditions of the 2025 licensing agreement. The term is from January 28, 2025, to January 27, 2028 (inclusive of the start and end dates), with a monthly licensing fee of 0.218 million HKD. Mr. Chan, a non-executive director, chairman, and controlling shareholder of JBM HEALTHCARE, holds approximately 59.92% of the issued shares in JACOBSON PHARMA.

Sina Hong Kong StockFeb 28 12:46